nafamostat has been researched along with Cells, Neoplasm Circulating in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kimura, T | 1 |
| Fuchimoto, S | 1 |
| Iwagaki, H | 1 |
| Orita, K | 1 |
1 other study available for nafamostat and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
[The inhibitory effect of nafamostat mesilate (FUT-175) on liver metastasis].
Topics: Animals; Benzamidines; Collagenases; Colonic Neoplasms; Fibrinolysin; Guanidines; Liver Neoplasms, E | 1993 |